سعر كالسيوم كلورايد 100مجم/مل امبول 2025

• Treatment of adult and pediatric patients with acute symptomatic hypocalcemia.Population: Adults and pediatric patientsDailyMed (U.S. NLM)

• Reported: paraesthesia on rapid injection, calcium taste, heat wave, local burning, extravasation/injection-site reactions, peripheral vasodilatation, decreased blood pressure.International label, same formulation · DailyMed (U.S. NLM)

• Contraindicated in ventricular fibrillation; asystole and electromechanical dissociation; newborns (≤28 days) if ceftriaxone IV is required or expected.International label, same formulation · DailyMed (U.S. NLM)

• Rapid injection may cause hypotension, bradycardia, arrhythmias, syncope; risk of tissue necrosis/calcinosis with extravasation; aluminum toxicity with prolonged use and renal impairment; do not mix/administer simultaneously with ceftriaxone.International label, same formulation · DailyMed (U.S. NLM)

• DigoxinMajorAvoid concomitant use; hypercalcemia increases digoxin toxicity risk; if unavoidable monitor ECG and calcium.DailyMed (U.S. NLM)
• CeftriaxoneMajorDo not mix or co-administer via Y-site; contraindicated in neonates ≤28 days.DailyMed (U.S. NLM)
• Calcium channel blockersModerateMay reduce response to calcium channel blockers; monitor blood pressure if concomitant use unavoidable.DailyMed (U.S. NLM)

• Treatment of acute symptomatic hypocalcemia in pregnancy is not expected to cause major birth defects, miscarriage, or adverse maternal/fetal outcomes; untreated maternal hypocalcemia carries risks.International label, same formulation · DailyMed (U.S. NLM)
• Calcium is present in human milk; approved doses not expected to harm a breastfed infant.International label, same formulation · DailyMed (U.S. NLM)

English text not available for this section.